US stock insider trading | LeonaBio disclosed 5 insider transactions on March 5

K-LinePoet · 2026-04-09T11:30:03+00:00

LeonaBio disclosed insider trading on March 5, 2026, with executives and directors selling multiple stocks on March 4, totaling several ten thousand dollars. The company focuses on developing small drug molecules to treat neurodegenerative diseases.

K-LinePoet

2026-04-09 11:30:03

Abstract generation in progress

On March 5, 2026, LeonaBio (LONA) disclosed five insider trading transactions. Director Litton Mark James sold 5,156 shares on March 4, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 5, 2026	Executive	San Martin Javier	March 4, 2026	Sell	1,720	5.37	9,236.40
March 5, 2026	Executive	Renninger Robert	March 4, 2026	Sell	906	5.37	4,865.22
March 5, 2026	Executive	Worthington Mark	March 4, 2026	Sell	1,328	5.37	7,131.36
March 5, 2026	Executive	CHURCH KEVIN	March 4, 2026	Sell	1,359	5.37	7,297.83
March 5, 2026	Director	Litton Mark James	March 4, 2026	Sell	5,156	5.37	$27.7k
January 5, 2026	Executive	Worthington Mark	January 2, 2026	Sell	876	6.88	6,026.88
January 5, 2026	Executive	CHURCH KEVIN	November 18, 2025	Buy	1,000	2.31	2,310.00
January 5, 2026	Executive	Renninger Robert	January 2, 2026	Sell	297	6.88	2,043.36
January 5, 2026	Executive	Renninger Robert	November 18, 2025	Buy	1,000	2.31	2,310.00
January 5, 2026	Executive	San Martin Javier	January 2, 2026	Sell	1,644	6.88	11.3k

【Company Information】

LeonaBio, Inc. was incorporated in Washington State on March 31, 2011, as M3 Biotechnology, Inc., and re-registered as a corporation in Delaware on October 27, 2015. The company is a late-stage biopharmaceutical firm focused on developing small-molecule drugs to restore neuronal health and prevent neurodegeneration. Its main drug candidates, lasofoxifene and ATH-1105, are novel small-molecule therapies aimed at treating currently limited or ineffective destructive diseases. LeonaBio is committed to scientific excellence and patient-centered innovation, striving to develop meaningful new therapies for those in greatest need.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.